A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

This resolution states the Senate's position on the abortion medication mifepristone and how it is regulated. It states that FDA policies on access to medication abortion must be based on a transparent scientific review of the full body of medical evidence and on the burdens rules place on patients and the health care system. It states that the FDA has found mifepristone safe and effective in multiple reviews, including when prescribed by telemedicine and dispensed by mail or at a pharmacy. It also states that keeping and expanding access to medication abortion, including telemedicine prescribing and mail or pharmacy dispensing, is important for equal access to abortion. The resolution expresses a position and does not change any law.

Full text and official record on Congress.gov

Sponsors

• Elizabeth Warren Democrat sponsor
• 46 cosponsors